Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)
Evaluate the potential effect of hepatic impairment on the pharmacokinetics, safety and tolerability of BAY1002670 (vilaprisan)
Leiomyoma
DRUG: Vilaprisan (BAY1002670)
Area under the concentration vs. time curve in plasma from zero to infinity (AUCu) (unbound), Exposure of Vilaprisan in plasma following a single dose administration, At pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours and at 1, 2, 3, 7, 10, 13, 16, 20 days|Maximum observed (unbound) drug concentration (Cmax,u), Maximum observed (unbound) drug concentration (Cmax,u) in measured matrix after a single dose administration, At pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 16 hours and at 1, 2, 3, 7, 10, 13, 16, 20 days
Frequency of Treatment Emergent Adverse Events, Frequency of Treatment Emergent Adverse Events as a measure of safety and tolerability, Up to 20 days|Severity of Treatment Emergent Adverse Events, The intensity of an AE is classified according to the following categories:

* Mild
* Moderate
* Severe, Up to 20 days|Changes in blood laboratory parameters, Changes in blood laboratory parameters including hematology, clotting status, serum chemistry, Up to 20 days|Changes in urine laboratory parameters, Changes in urine laboratory parameters including urine analysis, urine pregnancy tests, Up to 20 days|Changes in Vital Signs, Changes in Vital Signs, including blood pressure, pulse, body temperature, Up to 20 days|Changes in Electrocardiogram (ECG), ECG (12-lead) after â‰¥10 minutes supine rest, Up to 20 days
Evaluate the potential effect of hepatic impairment on the pharmacokinetics, safety and tolerability of BAY1002670 (vilaprisan)